Promising breast cancer study pulled before it started
NCT ID NCT06829199
First seen Feb 22, 2026 · Last updated May 18, 2026 · Updated 11 times
Summary
This study was designed to see if adding the experimental drug boserolimab to standard chemotherapy and immunotherapy before surgery could help people with high-risk early-stage triple-negative breast cancer. Researchers planned to check safety and whether the cancer completely disappeared by the time of surgery. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cheng Kung University Hospital ( Site 0901)
Tainan, 704, Taiwan
-
Optum Care Cancer Center ( Site 0004)
Las Vegas, Nevada, 89102, United States
Conditions
Explore the condition pages connected to this study.